Personalis Total Current Assets 2018-2024 | PSNL

Personalis total current assets from 2018 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Personalis Annual Total Current Assets
(Millions of US $)
2023 $147
2022 $200
2021 $318
2020 $221
2019 $140
2018 $30
2017 $
Personalis Quarterly Total Current Assets
(Millions of US $)
2024-06-30 $113
2024-03-31 $120
2023-12-31 $147
2023-09-30 $148
2023-06-30 $161
2023-03-31 $183
2022-12-31 $200
2022-09-30 $222
2022-06-30 $260
2022-03-31 $294
2021-12-31 $318
2021-09-30 $329
2021-06-30 $354
2021-03-31 $373
2020-12-31 $221
2020-09-30 $224
2020-06-30 $120
2020-03-31 $135
2019-12-31 $140
2019-09-30 $140
2019-06-30 $176
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.261B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00